Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

11294	Companies
250971	Keywords
179882	Articles
136839	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 07/30/2025 at 15:00, 1 year 3 months ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center

Xenetic Biosciences DNase I PeriNess Large B Cell Lymphoma Anti-CD19 CAR T Cells
BRIEF

published on 07/23/2025 at 14:35, 1 year 3 months ago

Xenetic Biosciences étend sa collaboration avec Scripps Research

Biosciences Xénétiques Thérapie Par Cellules CAR-T Développement Préclinique Plateforme DNase-I Collaboration En Oncologie
BRIEF

published on 07/23/2025 at 14:35, 1 year 3 months ago

Xenetic Biosciences Expands Collaboration with Scripps Research

Xenetic Biosciences CAR T-cell Therapy Preclinical Development DNase-I Platform Oncology Collaboration
PRESS RELEASE

published on 07/23/2025 at 14:30, 1 year 3 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 1 year 3 months ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 1 year 3 months ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 1 year 3 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 1 year 5 months ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 1 year 5 months ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 1 year 5 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I

Accesswire

Published on 11/06/2026 at 22:15, 1 day 15 hours ago

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 1 hour ago

Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 1 hour ago

Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 1 hour ago

Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/06/2026 at 10:00, 2 days 4 hours ago

Mongolia Tax Audit

View all ACCESSWIRE

EQS Group

Published on 11/08/2026 at 12:10, 1 hour 53 minutes ago

GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/08/2026 at 10:15, 3 hours 48 minutes ago

2026 China International Intelligent Communication Forum Held in Wuxi
Published on 11/07/2026 at 13:35, 1 day ago

Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 1 day 17 hours ago

African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 1 day 17 hours ago

L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication

Les Echos

Published on 11/06/2026 at 19:06, 1 day 18 hours ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 1 day 18 hours ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 1 day 19 hours ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 1 day 19 hours ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 18:00, 1 day 20 hours ago

ICADE - CP - Notation crédit S&P

View all LES ECHOS COMFI WIRE